Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study
eClinicalMedicine（2023）
摘要
Axcella Therapeutics.
更多查看译文
关键词
Long COVID,Mitochondrial dysfunction,Fatigue
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要